Introduction：Basic information about CAS 129-74-8|Buclizine dihydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Buclizine dihydrochloride |
|---|
| CAS Number | 129-74-8 | Molecular Weight | 505.950 |
|---|
| Density | / | Boiling Point | 520.1ºC at 760 mmHg |
|---|
| Molecular Formula | C28H35Cl3N2 | Melting Point | 230-240ºC |
|---|
| MSDS | / | Flash Point | 268.3ºC |
|---|
Names
| Name | anileridine dihydrochloride |
|---|
| Synonym | More Synonyms |
|---|
Buclizine dihydrochloride BiologicalActivity
| Description | Buclizine dihydrochloride is an orally active antihistamine antiallergic compound. Buclizine dihydrochloride is a potent teratogen in the rat[1][2][3]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Immunology/Inflammation >>Histamine ReceptorResearch Areas >>Inflammation/ImmunologySignaling Pathways >>GPCR/G Protein >>Histamine Receptor |
|---|
| In Vitro | Buclizine (0-100 μM, 72 h) inhibited cancer cell growth by binding to TCTP and induction of cell differentiation[3]. Cell Proliferation Assay[3]. Cell Line: MCF-7 cells[3]. Concentration: 0-100 μM. Incubation Time: 72 h. Result: The IC50 was 19.18 ± 5.32 μM. |
|---|
| In Vivo | Buclizine dihydrochloride (≥40 mg/kg) exhibits teratogenic effect[1]. Buclizine dihydrochloride exhibits the t1/2 of ~10 h via oral administration[2]. Animal Model: Eighty-seven mature female rats weighing 240±20 grams[1]. Dosage: 30-200 mg/kg. Administration: From days 10 to 15. Result: Exhibits teratogenic effect dose-dependently when ≥40 mg/kg. |
|---|
| References | [1]. C T King, et al. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol. 1966 May 1;95(1):109-11. [2]. Nawab Sher, et al. Simultaneous determination of antihistamine anti-allergic drugs, cetirizine, domperidone, chlorphenamine maleate, loratadine, meclizine and buclizine in pharmaceutical formulations, human serum and pharmacokinetics application. Analytical methods • March 2014. [3]. Ean-Jeong Seo, et al. Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget . 2016 Mar 29;7(13):16818-39. |
|---|
Chemical & Physical Properties
| Boiling Point | 520.1ºC at 760 mmHg |
|---|
| Melting Point | 230-240ºC |
|---|
| Molecular Formula | C28H35Cl3N2 |
|---|
| Molecular Weight | 505.950 |
|---|
| Flash Point | 268.3ºC |
|---|
| Exact Mass | 504.186584 |
|---|
| PSA | 6.48000 |
|---|
| LogP | 8.02450 |
|---|
| Vapour Pressure | 6.44E-11mmHg at 25°C |
|---|
| InChIKey | SDBHDSZKNVDKNU-UHFFFAOYSA-N |
|---|
| SMILES | CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1.Cl.Cl |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- TL0280000
- CHEMICAL NAME :
- Piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-alpha-phenylbenzyl )-, dihydrochloride
- CAS REGISTRY NUMBER :
- 129-74-8
- LAST UPDATED :
- 199701
- DATA ITEMS CITED :
- 4
- MOLECULAR FORMULA :
- C28-H33-Cl-N2.2Cl-H
- MOLECULAR WEIGHT :
- 506.00
- WISWESSER LINE NOTATION :
- T6N DNTJ AYR&R DG& D1R DX1&1&1 &GH 2
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 2100 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - excitement Lungs, Thorax, or Respiration - other changes
- REFERENCE :
- JAPMA8 Journal of the American Pharmaceutical Association, Scientific Edition. (Washington, DC) V.29-49, 1940-60. For publisher information, see JPMSAE. Volume(issue)/page/year: 43,653,1954
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 430 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - excitement Lungs, Thorax, or Respiration - other changes
- REFERENCE :
- JAPMA8 Journal of the American Pharmaceutical Association, Scientific Edition. (Washington, DC) V.29-49, 1940-60. For publisher information, see JPMSAE. Volume(issue)/page/year: 43,653,1954 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 360 mg/kg
- SEX/DURATION :
- female 10-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- REFERENCE :
- AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 95,109,1966
|
Safety Information
Synonyms
| 1-(p-Chlorobenzhydryl)-4-(p-tert-butylbenzyl)piperazine dihydrochloride |
| Posdel |
| 1-(p-Chlorobenzhydryl)-4-(p-tert-butylbenzyl)diethylenediamine dihydrochloride |
| 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine dihydrochloride |
| MFCD00242700 |
| Buclina |
| 1-(4-(tert-Butyl)benzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine dihydrochloride |
| 1-(p-tert-Butylbenzyl)-4-(p-chloro-a-phenylbenzyl)piperazine Dihydrochloride |
| 1-[(4-Chlorophenyl)(phenyl)methyl]-4-[4-(2-methyl-2-propanyl)benzyl]piperazine dihydrochloride |
| Postafen |
| BUCLIZINE, DIHYDROCHLORIDE |
| buclizine hydrochloride |
| Piperazine, 1- (p-tert-butylbenzyl)-4-(p-chloro-α-phenylbenzyl)-, dihydrochloride |
| buclizine dihydrochloride |
| Longifene |
| Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, hydrochloride (1:2) |
| 1-(p-tert-Butylbenzyl)-4-(p-chloro-α-phenylbenzyl)piperazine dihydrochloride |
| Piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-α-phenylbenzyl)-, dihydrochloride |
